By far the most frequently mutated genes in the pancreatic tumor cohorts are KRAS with 75% of affected patients and TP53 with 65% followed by CDKN2A and SMAD4 with 20%, respectively. This evidence concerns the gene CDKN2A and pancreatic neoplasm.